1. Home
  2. RDNW vs ZNTL Comparison

RDNW vs ZNTL Comparison

Compare RDNW & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDNW
  • ZNTL
  • Stock Information
  • Founded
  • RDNW 2013
  • ZNTL 2014
  • Country
  • RDNW United States
  • ZNTL United States
  • Employees
  • RDNW N/A
  • ZNTL N/A
  • Industry
  • RDNW EDP Services
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDNW Technology
  • ZNTL Health Care
  • Exchange
  • RDNW Nasdaq
  • ZNTL Nasdaq
  • Market Cap
  • RDNW 129.4M
  • ZNTL 118.3M
  • IPO Year
  • RDNW N/A
  • ZNTL 2020
  • Fundamental
  • Price
  • RDNW $5.18
  • ZNTL $1.34
  • Analyst Decision
  • RDNW Hold
  • ZNTL Buy
  • Analyst Count
  • RDNW 1
  • ZNTL 7
  • Target Price
  • RDNW $4.00
  • ZNTL $6.17
  • AVG Volume (30 Days)
  • RDNW 56.4K
  • ZNTL 678.5K
  • Earning Date
  • RDNW 11-04-2025
  • ZNTL 11-10-2025
  • Dividend Yield
  • RDNW N/A
  • ZNTL N/A
  • EPS Growth
  • RDNW N/A
  • ZNTL N/A
  • EPS
  • RDNW N/A
  • ZNTL N/A
  • Revenue
  • RDNW $1,095,200,000.00
  • ZNTL $26,865,000.00
  • Revenue This Year
  • RDNW N/A
  • ZNTL N/A
  • Revenue Next Year
  • RDNW $7.73
  • ZNTL N/A
  • P/E Ratio
  • RDNW N/A
  • ZNTL N/A
  • Revenue Growth
  • RDNW N/A
  • ZNTL N/A
  • 52 Week Low
  • RDNW $1.46
  • ZNTL $1.01
  • 52 Week High
  • RDNW $7.06
  • ZNTL $4.00
  • Technical
  • Relative Strength Index (RSI)
  • RDNW N/A
  • ZNTL 41.48
  • Support Level
  • RDNW N/A
  • ZNTL $1.30
  • Resistance Level
  • RDNW N/A
  • ZNTL $1.43
  • Average True Range (ATR)
  • RDNW 0.00
  • ZNTL 0.09
  • MACD
  • RDNW 0.00
  • ZNTL -0.00
  • Stochastic Oscillator
  • RDNW 0.00
  • ZNTL 37.50

About RDNW RideNow Group Inc.

RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: